← Leaderboards
Weei-Chin Lin
Baylor College Of Medicine
$10,211,771
Attributed
$13,086,333
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,086,333 · 7
By mechanism
R01$10,679,424 · 4
T32$2,027,697 · 2
R21$379,212 · 1
Top collaborators
- Fang-Tsyr Lin12 shared
- Rachel Nicole Arey1 shared
- David Loren Nelson1 shared
- Stephanie A Pangas1 shared
- Fred A Pereira1 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Fang-Tsyr Lin$3,618,481
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseIn VivoProteinsMediatingRegulationMalignant NeoplasmsNovel TherapeuticsEventDna DamagePathway InteractionsTherapeutic TargetCancer CellApoptosisCancer TherapyGrowthNormal CellCellsLeadMalignant Breast NeoplasmXenograft ProcedureNew Therapeutic TargetTumorApoptoticGain Of Function
Grant awards (43)
Training Program in Cell and Molecular Biology$852,721
T32 · FY2025 · GM
Novel therapeutics for targeting checkpoint dysfunction in cancer$382,469
R01 · FY2025 · CA · contact PI
14-3-3tau drives estrogen receptor loss and breast cancer progression$366,000
R01 · FY2025 · CA · contact PI
Novel therapeutics for targeting checkpoint dysfunction in cancer$363,346
R01 · FY2024 · CA · contact PI
14-3-3tau drives estrogen receptor loss and breast cancer progression$347,701
R01 · FY2024 · CA · contact PI
Novel therapeutics for targeting checkpoint dysfunction in cancer$374,819
R01 · FY2023 · CA · contact PI
14-3-3tau drives estrogen receptor loss and breast cancer progression$366,000
R01 · FY2023 · CA · contact PI
Novel therapeutics for targeting checkpoint dysfunction in cancer$382,469
R01 · FY2022 · CA · contact PI
Novel therapeutics for targeting checkpoint dysfunction in cancer$362,569
R01 · FY2021 · CA · contact PI
Novel therapeutics for targeting checkpoint dysfunction in cancer$362,569
R01 · FY2020 · CA · contact PI
Novel therapeutics for targeting checkpoint dysfunction in cancer$351,691
R01 · FY2019 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$345,926
R01 · FY2019 · CA · contact PI
Novel therapeutics for targeting checkpoint dysfunction in cancer$362,569
R01 · FY2018 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$356,625
R01 · FY2018 · CA · contact PI
BCM Oncology Scholars Training Program$258,995
T32 · FY2018 · CA · contact PI
Novel therapeutics for targeting checkpoint dysfunction in cancer$362,569
R01 · FY2017 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$356,625
R01 · FY2017 · CA · contact PI
BCM Oncology Scholars Training Program$261,630
T32 · FY2017 · CA · contact PI
New mechanisms of breast cancer metastasis and loss of estrogen receptor driven by 14-3-3$172,369
R21 · FY2017 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$356,625
R01 · FY2016 · CA · contact PI
BCM Oncology Scholars Training Program$256,699
T32 · FY2016 · CA · contact PI
New mechanisms of breast cancer metastasis and loss of estrogen receptor driven by 14-3-3$206,843
R21 · FY2016 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$355,875
R01 · FY2015 · CA · contact PI
BCM Oncology Scholars Training Program$268,078
T32 · FY2015 · CA · contact PI
Therapeutic Targeting of Oncogenic Stress in Cancer Treatment$299,689
R01 · FY2014 · CA · contact PI
BCM Oncology Scholars Training Program$129,574
T32 · FY2014 · CA · contact PI
Therapeutic Targeting of Oncogenic Stress in Cancer Treatment$290,420
R01 · FY2013 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$288,232
R01 · FY2013 · CA · contact PI
Therapeutic Targeting of Oncogenic Stress in Cancer Treatment$308,957
R01 · FY2012 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$306,630
R01 · FY2012 · CA · contact PI
Therapeutic Targeting of Oncogenic Stress in Cancer Treatment$308,957
R01 · FY2011 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$306,630
R01 · FY2011 · CA · contact PI
Therapeutic Targeting of Oncogenic Stress in Cancer Treatment$318,513
R01 · FY2010 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$316,113
R01 · FY2010 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$301,097
R01 · FY2009 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$278,662
R01 · FY2008 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$49,000
R01 · FY2008 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$253,662
R01 · FY2007 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$47,742
R01 · FY2007 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$286,638
R01 · FY2006 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$29,568
R01 · FY2006 · CA · contact PI
The ATM/E2F1 Pathway in DNA Damage and Growth Control$267,525
R01 · FY2005 · CA
The ATM/E2F1 Pathway in DNA Damage and Growth Control$264,942
R01 · FY2004 · CA